Maynard Um
-
-
-
-
-
-
-
Moderna (MRNA) PT Raised to $89 at Morgan Stanley
-
-
-
-
-
-
-
Trump Administration Weighs Order On Autism And Vaccines - Bloomberg
-
-
-
-
-
-
-
Merck (MRK) call put ratio 2 calls to 1 put into quarter results
-
-
-
-
-
-
-
FDA approves Merck's Lipfendra as first oral PCSK9 inhibitor
-
-
-
-
-
-
-
Merck (MRK) PT Raised to $141 at BofA Securities
-
-
-
-
-
-
-
Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASC
-
-
-
-
-
-
-
Merck to present oncology data across 25 cancer types at ASCO 2026
-
445,672 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

